<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669186</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00039201-1</org_study_id>
    <nct_id>NCT02669186</nct_id>
  </id_info>
  <brief_title>Effects of Anesthetic Technique on NK Cells</brief_title>
  <official_title>Effects of Anesthetic Technique on Natural Killer Cell Population and Cytotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a pilot prospective, single-blinded, randomized controlled trial
      evaluating the effects of two routine, standard-of-care, anesthetic techniques on natural
      killer cell population size and cytotoxicity in patients undergoing exploratory abdominal
      laparotomies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Natural Killer Cell Cytotoxicty</measure>
    <time_frame>One Year</time_frame>
    <description>Cytotoxicity will be assessed using Flow Cytometric analysis of cell receptor expression.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pain</condition>
  <condition>Anesthesia</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>'Bupivacaine + Fentanyl' (Opioid Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine (Local Anesthetic Group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine + Fentanyl</intervention_name>
    <description>General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.</description>
    <arm_group_label>'Bupivacaine + Fentanyl' (Opioid Group)</arm_group_label>
    <other_name>Sublimaze</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control</description>
    <arm_group_label>Bupivacaine (Local Anesthetic Group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 80 years old of either gender

          -  Diagnosis of abdominal tumor scheduled for exploratory laparotomy with study surgeon

          -  Must be able to have an epidural

        Exclusion Criteria:

          -  ASA IV and above

          -  Intolerance, allergy, or contraindication to use of either fentanyl or bupivacaine.

          -  Significant coronary artery disease (abnormal stress test, myocardial infarction
             within the last 3 months)

          -  Uncontrolled hypertension (BP &gt; 140/90)

          -  Cardiac arrhythmias particularly prolonged QT syndrome

          -  Drugs known to cause prolonged qT: class IA antiarrhythmics (quinidine, procainamide,
             dysopyramide), class III antiarrhythmics (sotalol, dofetalide, ibutalide, amiodarone),
             haloperidol, thioridazine, arsenic trioxide, HIV protease inhibitors, tricyclic
             antidepressants

          -  Individuals with significant psychological disorders including: schizophrenia, mania,
             bipolar disorder or psychosis

          -  Pregnant or lactating women

          -  Morbid obesity (BMI &gt; 40 kg/m2) AND/OR weight &gt; 150 kg

          -  Chronic renal failure ( creatinine &gt; 2.0 mg/dL)

          -  Liver failure e.g., active cirrhosis

          -  Alcohol or substance abuse within in the past 3 months

          -  Uncorrected hypokalemia, hypomagnesemia, hypocalcemia (can be due to diuretics,
             mineralocorticoid use, laxatives)

          -  Neuropathic pain

          -  Chronic opioid consumption (&gt;30mg oxycodone or greater per day)

          -  Cachexia from any cause

          -  Systemic use of corticosteroids for greater than 2 weeks in the 6 months prior to
             surgery

          -  HIV or other immunosuppressive condition

          -  Preoperative INR &gt; 1.4 or platelet count &lt; 100

          -  Sepsis or overlying skin cellulitis at epidural catheter insertion site

          -  Inability to tolerate/unwillingness to have an epidural catheter for
             intraoperative/postoperative pain control for any reason, including prior back surgery
             resulting in distorted anatomy that precludes neuraxial anesthesia.

          -  Inability to tolerate an epidural solution of either fentanyl or bupivacaine or needs
             another form of specialized pain control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roya Yumul, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Program Director, Department of Anesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer L Ross, MD, PhD</last_name>
    <phone>310-423-1682</phone>
    <email>jennifer.ross2@cshs.org</email>
  </overall_contact>
  <reference>
    <citation>Buckley A, McQuaid S, Johnson P, Buggy DJ. Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study. Br J Anaesth. 2014 Jul;113 Suppl 1:i56-62. doi: 10.1093/bja/aeu200. Epub 2014 Jul 9.</citation>
    <PMID>25009196</PMID>
  </reference>
  <reference>
    <citation>Beilin B, Shavit Y, Hart J, Mordashov B, Cohn S, Notti I, Bessler H. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg. 1996 Mar;82(3):492-7.</citation>
    <PMID>8623949</PMID>
  </reference>
  <reference>
    <citation>Cata JP, Bauer M, Sokari T, Ramirez MF, Mason D, Plautz G, Kurz A. Effects of surgery, general anesthesia, and perioperative epidural analgesia on the immune function of patients with non-small cell lung cancer. J Clin Anesth. 2013 Jun;25(4):255-62. doi: 10.1016/j.jclinane.2012.12.007. Epub 2013 May 7.</citation>
    <PMID>23659826</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Roya Yumul, M.D.,PhD.</investigator_full_name>
    <investigator_title>Program Director, Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>analgesia</keyword>
  <keyword>cancer</keyword>
  <keyword>natural killer cell</keyword>
  <keyword>opioid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

